Health Care & Hospital Law,
Civil Litigation
Mar. 19, 2020
McKesson agrees to $175M opioid settlement with investors
Fighting off claims from federal prosecutors, state attorneys general and private plaintiffs, the country’s largest opioid distributor also consented to several measures intended to bolster corporate governance, including separating the chief executive officer and chairman roles, empowering its compliance committee and creating term limits for board members, among other efforts, according to court documents filed March 17.
McKesson Corp. agreed to pay $175 million to settle an investor lawsuit that alleges the company repeatedly failed to properly monitor suspicious opioid shipments.
Now fighting off litigation brought by the U.S. Justice Department, state attorneys general and private plaintiffs, the nation's largest opioid distributor also consented to several measures intended to bolster corporate governance, including separating the chief executiv...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In
Enewsletter Sign-up
Related Content
Civil Litigation
Drug makers not liable for city’s needle clean-up, lawyers argue
By Winston Cho
Government, Bankruptcy
25 states oppose tentative Purdue Pharma bankruptcy deal
By Malcolm Maclachlan
Health Care & Hospital Law, Civil Litigation
The long, winding road to settling the opioid litigation
By Harry J. Nelson
